Overview

HDDO-1614 Bio Equivalence Study

Status:
Completed
Trial end date:
2018-01-05
Target enrollment:
Participant gender:
Summary
A randomized, open-label, single-dose, crossover study
Phase:
Phase 1
Details
Lead Sponsor:
Hyundai Pharmaceutical Co., LTD.
Treatments:
Bazedoxifene
Cholecalciferol